AstraZeneca’s CEO Says AI Is Redefining How New Medicines Are Built

When Pascal Soriot walked onto the stage at the London biotech summit, he didn’t start with the usual profit forecasts or market share chatter. Instead, he spent a good five minutes talking about a subject that feels more at home in a science‑fiction novel than in a boardroom: artificial intelligence.

“We’re at a point where AI is no longer a nice‑to‑have toy,” Soriot said, his tone a mixture of excitement and caution. “It’s becoming the backbone of how we design, test and even manufacture new medicines.” He went on to explain that AI‑driven models are now being used to predict how a protein will fold, how a molecule will interact with a target, and even how a patient’s genetics might influence side‑effects. The result? Shorter discovery cycles and, crucially, a higher probability that a drug will survive the grueling clinical‑trial gauntlet.

In practical terms, AstraZeneca has integrated machine‑learning platforms across its R&D pipeline. Early‑stage teams employ deep‑learning algorithms to sift through millions of compounds in a matter of hours—something that used to take weeks of manual labor. Later‑stage researchers rely on predictive analytics to select trial sites, refine dosage regimens, and flag potential safety flags before they become costly setbacks.

The CEO highlighted a few recent successes. One oncology candidate, discovered with the help of an AI‑powered target‑validation tool, moved from hit to clinical candidate in just 18 months—roughly half the typical timeline. Another rare‑disease program, powered by a partnership with a leading cloud‑AI provider, has already shown a 30% improvement in predictive accuracy for patient response, according to internal data.

But Soriot was quick to note that AI isn’t a silver bullet. “You still need brilliant scientists, good chemistry and rigorous clinical practice,” he reminded the audience. “What AI does is amplify our expertise, help us ask better questions, and cut out a lot of the noise.” He also acknowledged the ethical and regulatory challenges that come with data‑heavy models, stressing the need for transparency, robust validation and ongoing dialogue with regulators.

Looking ahead, AstraZeneca plans to double its AI‑related investment over the next three years, channeling funds into both in‑house capabilities and external collaborations. The company is also setting up an “AI Innovation Hub” in Cambridge, designed to bring together data scientists, clinicians and biotech entrepreneurs under one roof.

For patients, the promise is clear: faster access to treatments that have been vetted more thoroughly from the get‑go. For investors, it could mean a healthier pipeline and, hopefully, a sturdier bottom line. As Soriot summed up, “If we can raise the odds of success even a little, the impact on people’s lives is massive.”